Drug-labels.com

Corzyna: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
500 mg, 375 mg, 750 mg, 1000 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Corzyna

Serious warnings and precautions box

What CORZYNA is used for:

CORZYNA is a medicine used to treat chest pain (stable angina) in adults. It is used along with other medicines in patients:

  • who cannot tolerate other antianginal therapies or
  • for whom other antianginal therapies do not work to control their chest pain (this includes beta-blockers and calcium channel blockers).

How CORZYNA works:

How CORZYNA works to treat your symptoms of angina is not exactly known.

The ingredients in CORZYNA are:

Medicinal ingredient(s): Ranolazine

Non-medicinal ingredients: HPMC 2910/hypromellose, hydroxypropylcellulose, iron oxide red, iron oxide yellow, macrogol/PEG, lactose monohydrate, magnesium stearate, copolymer based on ethyl acrylate and methacrylic acid, microcrystalline cellulose, polysorbate 80, polyvinyl alcohol, purified water, sodium hydroxide, sodium lauryl sulfate, talc, titanium dioxide, triacetin.

CORZYNA comes in the following dosage form(s):

Extended-release Tablets: 375 mg, 500 mg, 750 mg, and 1000 mg

  • CORZYNA can change the electrical activity (prolong the QT interval) of your heart. You should not take more than 1000 mg of CORZYNA twice a day.

Do not use CORZYNA if you:

  • Are allergic to ranolazine or to any of the other ingredients in CORZYNA (see list of non- medicinal ingredients above)
  • Have severe kidney disease
  • Have moderate to severe liver disease
  • Take any of the following medicines. These can have serious interactions with CORZYNA.

    • for arrhythmias: quinidine, procainamide, disopyramide, sotalol, ibutilide, amiodarone, dronedarone
    • for a fungal infection: ketoconazole, itraconazole, voriconazole, posaconazole
    • for an infection: clarithromycin
    • for depression: nefazodone
    • for HIV: nelfinavir, ritonavir, indinavir, lopinavir, saquinavir
    • for tuberculosis (TB): rifampicin, rifabutin, rifapentine
    • for seizures: phenobarbital, phenytoin, carbamazepine
    • St. John’s wort
  • Eat grapefruit, drink grapefruit juice or take products that contain grapefruit

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CORZYNA. Talk about any health conditions or problems you may have, including if you:

  • take medicines (prescription, over-the-counter (OTC) and natural health products)
  • have or have a family history of a heart problem, called ‘QT prolongation’ or ‘long QT syndrome’
  • have low electrolyte levels (such as low potassium, magnesium or calcium), conditions that can cause low electrolyte levels (such as persistent vomiting and eating disorders) or are taking medicines that can affect your electrolyte levels such as:

    • diuretics
    • laxatives
    • enemas
    • high dose corticosteroids
    • medicines for acid reflux or gastroesophageal reflux disease (GERD)
  • have liver problems
  • have kidney problems
  • are pregnant or plan to become pregnant. It is not known if CORZYNA will harm your unborn baby

  • are breastfeeding or plan to breastfeed. It is not known if CORZYNA passes into your breast milk. Your doctor will decide if you should breastfeed or if you should stop treatment with CORZYNA

Other warnings you should know about:

  • Patients over 75 years of age: You may be more sensitive to experiencing side effects.
  • Monitoring and Laboratory tests: Before you start treatment with CORZYNA and periodically during treatment your doctor should:

    • perform electrocardiograms (ECGs) to monitor your heart
    • do blood tests to check your electrolyte levels
    • check your kidney and liver function
  • Driving and using machinery: You should avoid driving a car, using machinery or doing tasks that require you to be alert until you know how CORZYNA affects you. CORZYNA may cause:

    • dizziness
    • blurred vision
    • you to feel confused
    • hallucinations: hearing, seeing or sensing things that are not there

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Serious drug interactions

Serious drug interactions with CORZYNA include:

  • strong CYP 3A4 inhibitors: (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nelfinavir, ritonavir, indinavir, saquinavir and grapefruit juice) are contraindicated.
  • CYP 3A4 inducers (e.g., rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John’s wort) are contraindicated, and
  • Class IA (e.g. procainamide, disopyramide) and Class III antiarrhythmics (e.g.: sotalol, ibutilide, amiodarone, dronedarone) are contraindicated.

The following may also interact with CORZYNA:

  • medicines for heart problems including arrhythmias: such as digoxin, propafenone, flecainide
  • medicines for bacterial, viral or fungal infection: such as erythromycin, rifampicin, rifabutin, rifapentine, fluconazole
  • medicines to prevent organ rejection after a transplant: such as cyclosporine, sirolimus, everolimus
  • medicines used to lower your cholesterol: such as simvastatin, lovastatin, atorvastatin
  • medicines for high blood pressure: such as metoprolol, diltiazem, verapamil
  • medicines for depression: such as imipramine, doxepin, amitriptyline
  • metformin – used to treat high blood sugar (diabetes)

    tacrolimus – used to treat eczema

How to take CORZYNA:

  • Take CORZYNA exactly as your doctor tells you.
  • Do not crush, break or chew the tablet. Swallow it whole.
  • Do not take more than 1000 mg twice a day.
  • Do not take more than 500 mg twice a day if you also take medicines such as diltiazem, verapamil, erythromycin, and fluconazole (moderate CYP 3A4 inhibitors)

Usual dose:

375 mg, 500 mg, 750 mg, or 1000 mg twice a day.

Overdose:

Signs of an overdose include:

  • low blood pressure
  • slow heart rate
  • muscle twitches
  • shaking
  • feeling unsteady or confused
  • dizziness
  • nausea and vomiting
  • trouble speaking / understanding
  • hallucinations
If you think you, or a person you are caring for, have taken too much CORZYNA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you missed a dose of this medication, you do not need to make up the missed dose. Skip the missed dose and continue with your next scheduled dose. Do not take two doses at the same time.

Possible side effects from using CORZYNA:

These are not all the possible side effects you may have when taking CORZYNA. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

  • Dizziness
  • Headache
  • Constipation
  • Nausea

Serious side effects and what to do about them

Frequency/Side Effect/SymptomTalk to your healthcare professionalStop taking this drug and get immediate medical help
Frequency/Side Effect/SymptomTalk to your healthcare professionalStop taking this drug and get immediate medical help
Only if severeIn all cases
Only if severeIn all cases
Uncommon
QT prolongation (changes in the electrical activity of your heart): dizziness, feeling faint or
✓
lightheaded, heart beating irregularly or fast, seizures
Kidney failure in people who already have severe kidney problems
✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15°C – 30°C).

Any unused product or waste material should be disposed of as biohazardous waste.

Keep out of reach and sight of children.

If you want more information about CORZYNA:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website www.kyepharma.com; or by calling 1-888-822-7126.

Date of Authorization: 2025-06-30

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02510219

Approved according to the text: June 30, 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Corzyna

Rx or OTC
Prescription (Rx)?
DIN 02510219, 02558947, 02558955, 02510227
Schedule(s) PRESCRIPTION
Active ingredient(s) Ranolazine
Dosage form(s) Tablet (Extended-Release)
Route(s) of administration Oral
Drug class (WHO ATC)
  1. C Cardiovascular system drugs
    1. C01 Cardiac therapy drugs
      1. C01E Other cardiac preparations
        1. C01EB Other plain cardiac preparations
          1. C01EB18 Ranolazine
Company KYE PHARMACEUTICALS INC.
Strengths and forms
DIN Strength Dosage form(s) Current status
02510219 500 MG Tablet (Extended-Release) Marketed May 3, 2021
02558947 375 MG Tablet (Extended-Release) Approved June 30, 2025
02558955 750 MG Tablet (Extended-Release) Approved June 30, 2025
02510227 1000 MG Tablet (Extended-Release) Marketed May 24, 2023

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.